PDF herunterladen
CC BY 4.0 · TH Open 2018; 02(03): e233-e241
DOI: 10.1055/s-0038-1666803
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey

Deirdre A. Lane
1   University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
2   Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
,
Juliane Meyerhoff
3   Boehringer Ingelheim Pharma International GmbH, Ingelheim am Rhein, Germany
,
Ute Rohner
3   Boehringer Ingelheim Pharma International GmbH, Ingelheim am Rhein, Germany
,
Gregory Y. H. Lip
1   University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
2   Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
› Institutsangaben Funding This work was supported by Boehringer Ingelheim Pharma International GmbH, Ingelheim am Rhein, Germany.
Weitere Informationen

Publikationsverlauf

02. März 2018

22. Mai 2018

Publikationsdatum:
05. Juli 2018 (online)

   Lizenzen und Reprints

Abstract

Background Global differences exist in the management of atrial fibrillation (AF), and cultural differences may influence patients' expectations and perceptions of healthcare. This survey investigated whether country-specific differences in patients' perceptions of AF and oral anticoagulation (OAC) exist and if recent stroke influences these perceptions.

Methods Cross-sectional survey of 937 adults with nonvalvular AF receiving OAC for stroke prevention was conducted across United States, Canada, Germany, France, and Japan. Thirty-minute online interviews conducted between April and November 2015 included AF patients with recent stroke, and newly diagnosed AF and established AF, both without recent stroke.

Results U.S. patients and those with recent stroke perceived AF as more serious (54.0 and 55.2%, respectively) and were more concerned about stroke (50.0 and 68.0%, respectively). Japanese patients were more likely to perceive AF as not serious (41.0%), but 50.4% were frequently concerned about stroke. Patients in the United States, Canada, and Germany and those without recent stroke preferred to be involved in OAC treatment decisions (either shared decision making or patient's choice), while French and Japanese patients and those with recent stroke preferred their doctor to choose. For all country groups, stroke prevention was the most important factor when choosing OAC.

Conclusion In this international cohort of AF patients, country-specific differences exist in patients' perceptions of AF, concerns about stroke, and preference for involvement in OAC treatment decisions; recent experience of stroke significantly influenced patients' values and preferences regarding AF and treatment. Stroke prevention was rated as the most important factor when choosing OAC treatment.

Keywords

atrial fibrillation - oral anticoagulation - patients' perceptions - patient survey - stroke knowledge
 

  • References

  • 1 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 2 Macle L, Cairns J, Leblanc K. , et al; CCS Atrial Fibrillation Guidelines Committee. 2016 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2016; 32 (10) 1170-1185
    CrossrefPubMedGoogle Scholar
  • 3 National Institute for Health and Clinical Excellence (NICE). Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence (UK); 2014
    Google Scholar
  • 4 You JJ, Singer DE, Howard PA. , et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e531S-e575S
    CrossrefPubMedGoogle Scholar
  • 5 Alonso-Coello P, Montori VM, Díaz MG. , et al. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. Health Expect 2015; 18 (06) 2318-2327
    CrossrefPubMedGoogle Scholar
  • 6 Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and preferences of physicians and patients with non-valvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol 2016; 32 (06) 747-753
    CrossrefPubMedGoogle Scholar
  • 7 Lahaye S, Regpala S, Lacombe S. , et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111 (03) 465-473
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Lane DA, Aguinaga L, Blomström-Lundqvist C. , et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2015; 17 (12) 1747-1769
    CrossrefPubMedGoogle Scholar
  • 9 Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. Curr Pharm Des 2015; 21 (05) 533-543
    PubMedGoogle Scholar
  • 10 Lane DA, Lip GY. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111 (03) 381-383
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 MacLean S, Mulla S, Akl EA. , et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e1S-e23S
    CrossrefPubMedGoogle Scholar
  • 12 Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 survey of atrial fibrillation and stroke: gaps in knowledge and perspective, opportunities for improvement. J Stroke Cerebrovasc Dis 2015; 24 (08) 1691-1700
    CrossrefPubMedGoogle Scholar
  • 13 Moia M, Mantovani LG, Carpenedo M. , et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med 2013; 8 (03) 237-243
    CrossrefPubMedGoogle Scholar
  • 14 Aliot E, Breithardt G, Brugada J. , et al; Atrial Fibrillation AWareness And Risk Education group; Atrial Fibrillation Association; European Heart Rhythm Association; Stroke Alliance for Europe; World Heart Federation. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010; 12 (05) 626-633
    CrossrefPubMedGoogle Scholar
  • 15 Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006; 110 (03) 354-358
    CrossrefPubMedGoogle Scholar
  • 16 Lip GY, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ. Oral anticoagulation in atrial fibrillation: a pan-European patient survey. Eur J Intern Med 2007; 18 (03) 202-208
    CrossrefPubMedGoogle Scholar
  • 17 McCabe PJ. What patients want and need to know about atrial fibrillation. J Multidiscip Healthc 2011; 4: 413-419
    PubMedGoogle Scholar
  • 18 Amara W, Larsen TB, Sciaraffia E. , et al. Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace 2016; 18 (01) 151-155
    CrossrefPubMedGoogle Scholar
  • 19 McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative study. J Cardiovasc Nurs 2011; 26 (04) 336-344
    CrossrefPubMedGoogle Scholar
  • 20 Borg Xuereb C, Shaw RL, Lane DA. Patients' and physicians' experiences of atrial fibrillation consultations and anticoagulation decision-making: a multi-perspective IPA design. Psychol Health 2016; 31 (04) 436-455
    CrossrefPubMedGoogle Scholar
  • 21 Devereaux PJ, Anderson DR, Gardner MJ. , et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323 (7323): 1218-1222
    CrossrefPubMedGoogle Scholar
  • 22 Böttger B, Thate-Waschke IM, Bauersachs R, Kohlmann T, Wilke T. Preferences for anticoagulation therapy in atrial fibrillation: the patients' view. J Thromb Thrombolysis 2015; 40 (04) 406-415
    CrossrefPubMedGoogle Scholar
  • 23 Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment. Pharmacoeconomics 2014; 32 (11) 1115-1127
    CrossrefPubMedGoogle Scholar
  • 24 Palacio AM, Kirolos I, Tamariz L. Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence 2015; 9: 133-138
    PubMedGoogle Scholar
  • 25 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54 (12) 1044-1054
    Google Scholar
  • 26 Hernández Madrid A, Potpara TS, Dagres N. , et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace 2016; 18 (03) 463-467
    CrossrefPubMedGoogle Scholar
  • 27 Potpara TS, Pison L, Larsen TB, Estner H, Madrid A, Blomström-Lundqvist C. ; Scientific Initiatives Committee, and European Heart Rhythm Association. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace 2015; 17 (03) 468-472
    CrossrefPubMedGoogle Scholar
  • 28 Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997; 44 (05) 681-692
    CrossrefPubMedGoogle Scholar
  • 29 Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 1999; 49 (05) 651-661
    CrossrefPubMedGoogle Scholar
  • 30 Hess EP, Coylewright M, Frosch DL, Shah ND. Implementation of shared decision making in cardiovascular care: past, present, and future. Circ Cardiovasc Qual Outcomes 2014; 7 (05) 797-803
    CrossrefPubMedGoogle Scholar
  • 31 Laidsaar-Powell RC, Butow PN, Bu S. , et al. Physician-patient-companion communication and decision-making: a systematic review of triadic medical consultations. Patient Educ Couns 2013; 91 (01) 3-13
    CrossrefPubMedGoogle Scholar
  • 32 Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation 2014; 129 (06) 704-710
    CrossrefPubMedGoogle Scholar
  • 33 Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010; 4: 51-60
    PubMedGoogle Scholar
  • 34 Potpara TS, Lane DA, Lip GY. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace 2015; 17 (04) 507-508
    CrossrefPubMedGoogle Scholar
  • 35 Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?. J Thromb Haemost 2013; 11 (02) 390-394
    CrossrefPubMedGoogle Scholar
  • 36 Assessment of an education and guidance program for Eliquis adherence in non-valvular atrial fibrillation (AEGEAN) study. Available at: www.clinicaltrials.gov ; NCT01884350. Accessed June 6, 2018
    PubMed
  • 37 Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015; 13 (04) 495-504
    CrossrefPubMedGoogle Scholar
  • 38 Shore S, Carey EP, Turakhia MP. , et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration. Am Heart J 2014; 167 (06) 810-817
    CrossrefPubMedGoogle Scholar
  • 39 Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013; 19 (09) e325-e332
    PubMedGoogle Scholar
  • 40 Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000; 320 (7246): 1380-1384
    CrossrefPubMedGoogle Scholar